Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 9/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.39 |
| ▸ | WNT1 | P04628 | 8/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776361 | 0.91 | BRAF (0.44) | BRAFGSK3BRHOACA2CA9 | |
| SCHEMBL16776298 | 0.87 | RHOA (0.39) | BRAFGSK3BDYRK1AWNT1RHOA | |
| SCHEMBL19670427 | 0.85 | DYRK1A (0.39) | BRAFGSK3BDYRK1AWNT1RHOA | |
| SCHEMBL16776365 | 0.83 | MPL (0.43) | BRAFCA2CA9GRIN1GRIN2B | |
| SCHEMBL16776347 | 0.81 | ALOX15 (0.38) | BRAFGSK3BDYRK1AGRIN1GRIN2B | |
| SCHEMBL20632880 | 0.81 | DYRK1A (0.39) | BRAFGSK3BDYRK1AWNT1RHOA | |
| SCHEMBL16776360 | 0.81 | HTR2C (0.46) | BRAF | |
| SCHEMBL16776380 | 0.80 | BRAF (0.46) | BRAFRHOA | |
| SCHEMBL16776366 | 0.80 | PHGDH (0.40) | CA2CA9SLC5A1KMO | |
| SCHEMBL19865030 | 0.79 | DYRK1A (0.40) | BRAFGSK3BDYRK1AWNT1RHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | BRAF 3419/4885GSK3B 1728/4885DYRK1A 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.